June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Vitamin D supplementation modulates Th2 immune response by inducing T regulatory cells in allergic conjunctivitis
Author Affiliations & Notes
  • Hyun Soo Lee
    Ophthalmology, Seoul St.Mary Hospital, Seoul, Korea (the Republic of)
  • Ji Young Kwon
    Ophthalmology, Seoul St.Mary Hospital, Seoul, Korea (the Republic of)
  • Chang Rae Rho
    Ophthalmology, Daejeon St. Mary's Hospital, Daejeon, Korea (the Republic of)
  • Jeewon Mok
    Ophthalmology, Seoul St.Mary Hospital, Seoul, Korea (the Republic of)
  • Choun-Ki Joo
    Ophthalmology, Seoul St.Mary Hospital, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Hyun Soo Lee, None; Ji Young Kwon, None; Chang Rae Rho, None; Jeewon Mok, None; Choun-Ki Joo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 843. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hyun Soo Lee, Ji Young Kwon, Chang Rae Rho, Jeewon Mok, Choun-Ki Joo; Vitamin D supplementation modulates Th2 immune response by inducing T regulatory cells in allergic conjunctivitis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):843.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The prevalence of allergic diseases is rapidly increasing worldwide, and allergic conjunctivitis (AC) is one of the most common diseases in eye clinics. Recently, Vitamin D deficiency has been shown to be associated with allergic disorders. However, the therapeutic potential of vitamin D for AC and the underlying mechanisms of its actions remain still unknown. This present study was designed to evaluate the efficacy of vitamin D to suppress the development of ovalbumin (OVA)-sensitized AC in a murine model.

Methods : Seven- to eight-week-old BALB/c mice were sensitized with OVA and aluminum hydroxide via intraperitoneal injection. Two weeks later, mice were challenged by OVA eyedrops for 12 days with intraperitoneal injection of vehicle or 1, 25-dihydroxyvitamin D3 (1,25(OH)2D3). We evaluated clinical signs, the infiltration of inflammatory cells into conjunctiva, regulatory T cells (Treg) in drainage LN, serum levels of OVA-specific IgE production, and Th2 cytokines secretion in vitro T cells assay through flow cytometry and ELISA. In addition, to evaluate inhibitory function of Treg cells, anti–CD25 blocking antibody or isotype control antibody was injected intravenously 2 day prior to, on the day of, and 5 day after topical OVA challenge.

Results : AC development and conjunctival infiltration of eosinophils (CD45+ Siglec-F+; p = 0.018 vs. vehicle) and mast cells (CD45+ c-kit+; p = 0.022 vs. vehicle) were significantly impaired with 1,25(OH)2D3 treatment. In addition, 1,25(OH)2D3 suppressed production of OVA-specific IgE in serum (p < 0.001 vs. vehicle) and Th2 cytokines in vitro T cell assays, such as IL-4 (p = 0.032 vs. vehicle) and IL-13 (p = 0.016 vs. vehicle), compared to vehicle group. Interestingly, 1,25(OH)2D3 led to increase Treg cells population in draining LNs and suppressive levels of clinical signs and inflammatory cells infiltration into conjunctivae were reversed by depleting Treg cells (p = 0.028 vs. isotype cotrol).

Conclusions : Our results suggest that vitamin D supplement alleviate allergic conjunctivitis, indicated by suppressing Th2 response in draining LNs and inflammatory cells infiltration into conjunctiva. vitamin D also increased population of Treg cells in draining LNs, which inhibited Th2 response. Therefore our results demonstrated new insight into the therapeutic potential of vitamin D for allergic diseases including asthma or atopic dermatitis

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×